Want to see IMRX full AI Analyst Report?
IMRX Stock Chart & Stats
$4.32
$0.04(0.93%)
At close: 4:00 PM EDT
$4.32
$0.04(0.93%)
Day’s Range― - ―
52-Week Range$2.90 - $10.08
Previous Close$4.39
Volume459.78K
Average Volume (3M)1.27M
Market Cap
$273.67M
Enterprise Value$187.79
Total Cash (Recent Filing)$156.69M
Total Debt (Recent Filing)$3.73B
Price to Earnings (P/E)―
Beta1.95
Next Earnings
Aug 12, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding64,697,230
10 Day Avg. Volume807,675
30 Day Avg. Volume1,267,347
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.33
Price to Sales (P/S)0.00
P/FCF Ratio-6.37
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.00Price Target Upside247.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.11
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Computational Biology / AI-driven DiscoveryImmuneering's AI/ML-driven discovery platform provides a durable R&D advantage by improving target identification and candidate selection. Over 2-6 months this reduces program attrition risk, accelerates IND readiness, and supports a more efficient pipeline build versus peers relying solely on traditional discovery.
Positive Phase 2a Atebimetinib Data And Phase 3 PlanRobust Phase 2a signals (OS, PFS, response and safety) plus an outlined path to a pivotal mid-2026 Phase 3 materially de-risks clinical development. This clinical validation strengthens the company's ability to progress to registrational studies and attract partners or funding over the next 2-6 months.
Experienced Finance Hire And Governance ContinuityHiring an experienced biotech CFO and securing shareholder votes for directors/auditor improve execution credibility and capital markets access. Coupled with low reported leverage, stronger finance leadership enhances ability to manage funding rounds and execute clinical milestones sustainably.
Bears Say
No Recurring Product RevenueAs a clinical-stage biotech without commercial products, Immuneering lacks predictable operating revenue. This structural absence of product cash flow leaves the company dependent on milestone/collaboration receipts and financings, constraining self-sustaining funding over the next several quarters.
High Cash Burn And Weak Cash GenerationMeaningful recurring negative operating and free cash flow highlights ongoing funding needs. Sustained burn at these levels implies reliance on external capital raises or deals to fund trials; this elevates dilution and execution risk if capital markets or partnership timing slip over the medium term.
Persistent Net Losses And Weak ProfitabilityLarge, recurring net losses with no material revenue base mean margins and returns are negative, limiting reinvestment capacity and shareholder returns. Continued losses drive equity volatility and heighten dependence on financing, increasing execution risk for planned pivotal trials and pipeline advancement.
Immuneering News
IMRX FAQ
What was Immuneering Corp. Class A’s price range in the past 12 months?
Immuneering Corp. Class A lowest stock price was $2.90 and its highest was $10.08 in the past 12 months.
What is Immuneering Corp. Class A’s market cap?
Immuneering Corp. Class A’s market cap is $273.67M.
When is Immuneering Corp. Class A’s upcoming earnings report date?
Immuneering Corp. Class A’s upcoming earnings report date is Aug 12, 2026 which is in 10 days.
How were Immuneering Corp. Class A’s earnings last quarter?
Immuneering Corp. Class A released its earnings results on May 15, 2026. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.252 by $0.042.
Is Immuneering Corp. Class A overvalued?
According to Wall Street analysts Immuneering Corp. Class A’s price is currently Undervalued.
Does Immuneering Corp. Class A pay dividends?
Immuneering Corp. Class A does not currently pay dividends.
What is Immuneering Corp. Class A’s EPS estimate?
Immuneering Corp. Class A’s EPS estimate is -0.27.
How many shares outstanding does Immuneering Corp. Class A have?
Immuneering Corp. Class A has 64,697,230 shares outstanding.
What happened to Immuneering Corp. Class A’s price movement after its last earnings report?
Immuneering Corp. Class A reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.252. Following the earnings report the stock price went up 0.389%.
Which hedge fund is a major shareholder of Immuneering Corp. Class A?
Currently, no hedge funds are holding shares in IMRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immuneering Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.00 (247.22% Upside)
$15.00 (247.22% Upside)
Blogger Sentiment
Bullish
IMRX Sentiment 70%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 181.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $36.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.8%
Last 30 Days <0.1%
Last 30 Days <0.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
323.84%
Trailing 12-Months
Company Description
Immuneering Corp. Class A
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
IMRX Stock 12 Month Forecast
Average Price Target
$15.00
▲(247.22% Upside)
Technical Analysis
Ownership Overview
9.38% Insiders
15.57% Mutual Funds
5.44% Other Institutional Investors
60.77% Public Companies and
Individual Investors